Evaluation of Biofield Modality on Viral Load of Hepatitis B and C Viruses

By Mahendra Kumar Trivedi1, Shrikant Patil1, Harish Shettigar1, Sambhu Charan Mondal2, Snehasis Jana2

1. Trivedi Global Inc. 2. Trivedi Science Research Laboratory Pvt. Ltd.

Published on


Study background: Nowadays, hepatitis is a major challenge for clinical research, regulatory bodies, and clinicians who are trying to assess the more effectiveness of antiviral therapy against patients. Viral load count is the amount of particular viral DNA or RNA in a blood samples. It is one of the surrogate biomarker of hepatitis. High viral load indicates that the immune system is failed to fight against viruses. The aim of this study was to evaluate the impact of biofield modality on hepatitis B virus (HBV) and hepatitis C virus (HCV) in terms of viral load as surrogate marker.

Method: The viral load assay was performed on stock human plasma samples of HBV and HCV before and after 7 days of biofield treatment using Roche COBAS® AMPLICOR analyzer according to manufacturer’s instructions. Viremia (viral DNA for HBV, RNA for HCV) was considered as surrogate marker for assessment of the impact of Mr. Trivedi’s biofield treatment.

Result: The viral load of HBV DNA in infected plasma samples showed a significant alteration in the biofield treated group as compared to control. Additionally, viral load count of HCV RNA in infected plasma samples was significantly reduced by 67% in the biofield treated group as compared to control. As the biofield treatment has significantly reduced HCV RNA, it could be beneficial for particularly HCV infected populations.

Conclusion: Altogether, data suggest that biofield treatment has significantly alteration in HBV and reduced the viral load count in HCV infected plasma samples and could be a suitable alternative treatment strategy for hepatitis patients in near future.


1. Block TM, Guo H, Guo JT (2007) Molecular virology of hepatitis B virus for clinicians. Clin Liver Dis 11: 685-706.

2. Marcellin P (2009) Hepatitis B and hepatitis C in 2009. Liver Int 29: 1-8.

3. Lok AS, McMahon BJ (2007) Chronic hepatitis B. Hepatology 45: 507-539.

4. Maynard JE (1990) Hepatitis B: global importance and need for control. Vaccine 8: S18-20.

5. Ott JJ, Stevens GA, Groeger J, Wiersma ST (2012) Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 30: 2212-2219.

6. Chisari FV, Isogawa M, Wieland SF (2010) Pathogenesis of hepatitis B virus infection. Pathol Biol (Paris) 58: 258-266.

7. Kim CW, Chang KM (2013) Hepatitis C virus: virology and life cycle. Clin Mol Hepatol 19: 17-25.

8. Alter MJ (1997) Epidemiology of hepatitis C. Hepatology 26: 62S-65S.

9. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, et al. (1999) The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341: 556-562.

10. Torbenson M, Thomas DL (2002) Occult hepatitis B. Lancet Infect Dis 2: 479-486.

11. Taha EA, Mekky MA, Morsy H, Saleh MA, Nafeh HM, et al. (2014) Study of the impact of viral load of hepatitis C on patients with concomitant psoriasis vulgaris. Arab J Gastroenterol 15: 98-102.

12. Franciscus A (2006) HCV Viral load tests. Hepatitis C Basics 2: 1-3.

13. Patel K, Muir AJ, McHutchison JG (2006) Diagnosis and treatment of chronic hepatitis C infection. BMJ 332: 1013-1017.

14. Kanwal F, Hoang T, Spiegel BM, Eisen S, Dominitz JA, et al. (2007) Predictors of treatment in patients with chronic hepatitis C infection - role of patient versus nonpatient factors. Hepatology 46: 1741-1749.

15. Manns MP, Wedemeyer H, Cornberg M (2006) Treating viral hepatitis C: efficacy, side effects, and complications. Gut 55: 1350-1359.

16. Running A (2015) Decreased cortisol and pain in breast cancer: biofield therapy potential. Evid Based Complement Alternat Med 2015: 1-7.

17. McTaggart L (2003) The Field. Harper Perennial, New York.

18. Maxwell J (1865) A dynamical theory of the electromagnetic field. Phil Trans R Soc Lond 155: 459-512.

19. Movaffaghi Z, Farsi M (2009) Biofield therapies: biophysical basis and biological regulations? Complement Ther Clin Pract 15: 35-37.

20. Trivedi MK, Patil S (2008) Impact of an external energy on Staphylococcus epidermis [ATCC-13518] in relation to antibiotic susceptibility and biochemical reactions-an experimental study. J Accord Integr Med 4: 230-235.

21. Trivedi MK, Patil S (2008) Impact of an external energy on Yersinia enterocolitica [ATCC-23715] in relation to antibiotic susceptibility and biochemical reactions: an experimental study. Internet J Alternat Med 6: 13.

22. Trivedi M, Bhardwaj Y, Patil S, Shettigar H and Bulbule A (2009) Impact of an external energy on Enterococcus faecalis [ATCC-51299] in relation to antibiotic susceptibility and biochemical reactions-An experimental study. J Accord Integr Med 5: 119-130.

23. Shinde V, Sances F, Patil S, Spence A (2012) Impact of biofield treatment on growth and yield of lettuce and tomato. Aust J Basic Appl Sci 6: 100-105.

24. Sances F, Flora E, Patil S, Spence A, Shinde V (2013) Impact of biofield treatment on ginseng and organic blueberry yield. Agrivita J Agric Sci 35: 22-29.

25. Trivedi MK, Tallapragada RM (2009) Effect of super consciousness external energy on atomic, crystalline and powder characteristics of carbon allotrope powders. Mater Res Innov 13: 473-480.

26. Trivedi MK, Patil S, Tallapragada RM (2013) Effect of biofield treatment on the physical and thermal characteristics of silicon, tin and lead powders. J Material Sci Eng 2: 125.

27. Trivedi MK, Patil S, Tallapragada RM (2013) Effect of biofield treatment on the physical and thermal characteristics of vanadium pantaoxide powders. J Material Sci Eng S11: 001.

28. Lopez VA, Bourne EJ, Lutz MW, Condreay LD (2002) Assessment of the COBAS Amplicor HBV Monitor Test for quantitation of serum hepatitis B virus DNA levels. J Clin Microbiol 40: 1972-1976.

29. Gerken G, Rothaar T, Rumi MG, Soffredini R, Trippler M, et al. (2000) Performance of the COBAS AMPLICOR HCV MONITOR test, version 2.0, an automated reverse transcription-PCR quantitative system for hepatitis C virus load determination. J Clin Microbiol 38: 2210-2214.

30. Block TM, London WT (2004) Surrogate markers of efficacy for medical treatment of viral hepatitis. Biotechnol Healthc 1: 42-48.

31. Rojo AD, Feld JJ (2010) Hepatitis B biomarkers: Clinical significance of the old and the new. Curr Hepatol Rep 9: 187-196.

32. Ernst E (1997) Complementary AIDS therapies: the good, the bad and the ugly. Int J STD AIDS 8: 281-285.

33. Minga TM, Koto FK, Egboki H, Suzuki K (2014) Effectiveness of biofield therapy for individuals with sickle cell disease in Africa. Altern Ther Health Med 20: 20-26.

34. Fried MW, Navarro VJ, Afdhal N, Belle SH, Wahed AS, et al. (2012) Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial. JAMA 308: 274-282.

35. Pradhan SC, Girish C (2006) Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J Med Res 124: 491-504.

36. Yu ZG, Song X (2001) Variable range hopping and electrical conductivity along the DNA double helix. Phys Rev Lett 86: 6018-6021.

37. Tran P, Alavi B, Gruner G (2000) Charge transport along the lambda-DNA double helix. Phys Rev Lett 85: 1564-1567.

38. Marshall RJ The best kept secret in nutrition: The body’s biofield communication system. Premier research labs. Austin, TX.

Cite this work

Researchers should cite this work as follows:

  • Trivedi MK, Patil S, Shettigar H, Mondal SC, Jana S (2015) Evaluation of Biofield Modality on Viral Load of Hepatitis B and C Viruses. J Antivir Antiretrovir 7: 083-088. doi:10.4172/jaa.1000123

  • Mahendra Kumar Trivedi; Shrikant Patil; Harish Shettigar; Sambhu Charan Mondal; Snehasis Jana (2019), "Evaluation of Biofield Modality on Viral Load of Hepatitis B and C Viruses," https://diagrid.org/resources/1802.

    BibTex | EndNote